Recent news on Sorafenib

Second-line Therapy With Sorafenib Improves Survival in Patients ...  -  25 May 2007
DG NewsThe phase 3 trial, presented on May 20 th , enrolled 903 patients worldwide and evaluated the efficacy of sorafenib (800 mg/day) versus placebo and best

AUA 2007 - Plenary Session: State-of-the-Art "Targeted Therapies ...  -  25 May 2007
UroToday,Sorafenib blocks the PDGRFR, VEGFR and the Raf pathways. In the initial trial the PFS was 24 months as compared to 6 weeks for placebo.

Onyx Pharmaceuticals to Present at Bank of America 2007 Health ...  -  May 24, 2007
PharmaLive.com (press release),...visit the company's web site at: http://www.onyx-pharm.com. Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.

Report On Kidney Cancer Symposium - Update On Targeted Therapies  -  May 14, 2007
Medical News Today (press release),Sorafenib was superior to placebo as 2nd line or salvage therapy in delaying time to progression in patients that had previously failed cytokine therapy.

Patient wins drug battle  -  May 2, 2007
Shropshire Star,He had been spending £3000 a month on the drug Sorafenib Nexaval because it has not been approved by the National Institute for Clinical Excellence.

Report On Kidney Cancer Symposium - Management Of Metastatic Sites ...  -  May 21, 2007
Medical News Today (press release),He reported his experience with interferon, sorafenib, and sunitinib in the treatment of metastatic RCC with bone metastases. Sunitinib was superior to the

Onyx Pharmaceuticals Reports First Quarter 2007 Financial Results  -  May 9, 2007
PR Newswire (press release),Onyx, with its collaborator, Bayer Pharmaceuticals Corporation, or Bayer, is marketing and developing Nexavar(R) (sorafenib) tablets, an anticancer drug

To Build a Killing Machine  -  May 9, 2007
Scientist,Meanwhile, Onyx had a partnership with Bayer to develop a more conventional small-molecule cancer therapy called sorafenib. Onyx had to prioritize the

Diabetes drug costs could soar 70% over next three years  -  May 18, 2007
Pharma Times (subscription),This sharp increase in the cost of treatment was due to the rapid adoption of expensive treatments such as Bayer's Nexavar (sorafenib), Celgene Corp's

Where Science Meets Policy: Kidney Cancer Patient Reported Outcome ...  -  May 11, 2007
Medical News Today (press release),In recent years, however, newer targeted agents (eg, sorafenib; sunitinib) have shown promise in improving clinical outcome.

Betaseron and Yasmin stoke sales and profits surge at Bayer  -  May 8, 2007
Pharma Times (subscription),The company was also enthusiastic about the performance of Nexavar (sorafenib), which is currently approved as a treatment for advanced kidney cancer,

ZymoGenetics Reports First Quarter 2007 Financial Results  -  May 3, 2007
PharmaLive.com (press release),The company is also enrolling patients in the Phase 1 part of its Phase 1/2 renal cell carcinoma trial combining IL-21 with sorafenib (a product of Bayer

US biotech drug spending rises while Congress debates over ...  -  26 Apr 2007
BiopharmaReporter.com,Revlimid (lenalidomide) for multiple myeloma and Pfizer's Sutent (sunitinib) and Bayer and Onyx' Nexavar (sorafenib), both used for kidney cancer.

Appeal date for cancer patient  -  Apr 24, 2007
Shropshire Star,Mr Green has been denied funding by the PCT for the drug Sorafenib Nexaval because it has not been approved by experts on the National Institute for

Idera Pharmaceuticals Announces Presentations of Preclinical Data ...  -  Apr 19, 2007
PipelineReview.com (press release),The first presentation covered a preclinical study in which Idera’s lead oncology candidate IMO-2055 in combination with the multikinase inhibitor sorafenib

Idera Pharmaceuticals Announces Presentations of Preclinical Data ...  -  Apr 18, 2007
PharmaLive.com (press release),..."The new data in a mouse model show IMO-2055 has additive antitumor activity with sorafenib, and adds to our previous data of additive antitumor activity by

Adnexus Therapeutics Announces Presentation at the American ...  -  Apr 18, 2007
PipelineReview.com (press release),In preclinical tumor models, CT-322 was compared to two approved pan-kinase inhibitors sunitinib and sorafenib. CT-322, sunitinib, and sorafenib each

Drug hope for patient  -  Apr 10, 2007
Shropshire Star,The trust says the drug, Sorafenib Nexaval, has not been approved by the National Institute for Health and Clinical Excellence (NICE) in England and Wales,

EUA - State Of The Art Lecture: Management Of Metastatic Renal Cancer  -  Apr 2, 2007
Medical News Today (press release),Sorafenib, a novel RAF kinase and VEGFR inhibitor is also an oral agent that improves progression-free survival in mRCC. As first line therapy for good

Eye cancer begins fight for life  -  Apr 20, 2007
West County Times,In addition to a chemo drip, for close to four months Shevenell has taken a daily dose of Sorafenib, a drug which Irwin describes as "the Porsche of

Idera Phama (IDP) Discloses Two Positive Presentations of its TLR9 ...  -  Apr 18, 2007
StreetInsider.com (subscription),...in combination with the multikinase inhibitor sorafenib, showed enhanced antitumor activity compared to either agent alone in a mouse xenograft model.

Ascenta Therapeutics Highlights Multiple Data Presentations at ...  -  Apr 13, 2007
Genetic Engineering News (press release),VEGFR Ascenta kinase inhibitor sorafenib Therapeutics (Nexavar(R)) --------- --------- ---------------------------------- -------------- Tuesday 3:30pm

Setback for Wyeth as FDA delays review on kidney cancer drug Torisel  -  Apr 10, 2007
Pharma Times (subscription),...it will come up against two recently-approved drugs for renal cell carcinoma, namely Pfizer's Sutent (sunitinib) and Bayer/Onyx' Nexavar (sorafenib) and

Overhauling clinical trials  -  Apr 5, 2007
Nature.com (subscription),...who helped design the trials that sampled Bayer's small molecule Nexavar (sorafenib) in multiple tumor types before settling on kidney cancer.

VioQuest Pharmaceuticals Adds Two New Products to Its Pipeline  -  Mar 30, 2007
PharmaLive.com (press release),In addition, HFS is being seen in patients receiving some of the newer tyrosine kinase class of therapies sorafenib (Nexavar(TM)).

Pfizer's Sutent gets boost in new urology guidelines  -  27 Mar 2007
Pharma Times (subscription),A trial comparing Bayer's Nexavar (sorafenib) and IFN alpha as first-line therapy is in progress. Meanwhile, Phase III data from a study involving

Nexavar (sorafenib) - the latest weapon in the fight against cancer  -  Mar 20, 2007
ic Wales,Why is it better: Trials have shown that sorafenib can make the cancer stop growing for longer than people taking a placebo. It has also been found to slow

Anger as new drug rejected on grounds of cost  -  Mar 21, 2007
ic Wales,The All Wales Medicines Strategy Group (AWMSG), which decides on funding of some drugs, rejected Nexavar, which is also known as sorafenib, on the grounds

Onyx Pharmaceuticals to Present at Lehman Global Healthcare Conference  -  Mar 16, 2007
PharmaLive.com (press release),...visit the company's web site at: www.onyx-pharm.com. NOTE: Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.

Medical Management of Patients With Head and Neck Cancer  -  Mar 1, 2007
Medscape (subscription)Elser and colleagues [9] from Toronto's Princess Margaret Hospital discussed the effects of sorafenib, an oral multikinase inhibitor that targets Raf kinase

Natural drugs undervalued in drug discovery  -  Mar 21, 2007
DrugResearcher.com,The drug the authors are referring to is Onyx's Nexavar (sorafenib), which was developed in conjunction with Bayer. The compound inhibits multiple kinases

Native kinase profiling  -  Mar 21, 2007
DrugResearcher.com,The problems involved in designing effective inhibitors are highlighted by the recent failure of Onyx' and Bayer's Nexavar (sorafenib) in a skin cancer

Experts back plea for cancer drugs  -  Feb 26, 2007
The Northern Echo,The experts, drawn from elite cancer centres from across the UK, want to see Sutent, also known as sunitinib, and Nexavar, also known as sorafenib,

Sign For Kidney Cancer Drug  -  Mar 16, 2007
Pembrokeshiretv.com,Sutent (sunitinib) & Nexavar (sorafenib) will be made available to Kidney Cancer patients throughout the United Kingdom on prescription and fully funded

Bayer has high hopes that cancer drug Nexavar will be huge  -  Mar 16, 2007
Pharma Times (subscription),However most excitement was reserved for the performance of Nexavar (sorafenib), which is currently approved as a treatment for advanced kidney cancer,

Improved Tolerability And Quality Of Life With Maintained Efficacy ...  -  Mar 12, 2007
Medical News Today (press release),With the development and FDA approval of the new targeted therapies (sunitinib and sorafenib), interferon therapy has been largely replaced as a consequence

International Symposium On Targeted Anticancer Therapies (TAT2007)  -  Mar 11, 2007
Medical News Today (press release),...oblimersen sodium, sorafenib, and sunitinib. All of these have been approved or are awaiting regulatory approval in various cancer indications.

New drugs for cancer therapy at international conference in Amsterdam  -  Mar 11, 2007
SpiritIndia,Amsterdam over the next three days are bevacizumab, cetuximab, dasatinib, erlotinib, lapatinib, nilotinib, oblimersen sodium, sorafenib, and sunitinib.

Cancer patient wins drug appeal  -  Feb 23, 2007
Lancashire Evening Telegraph,He had high hopes that his appeal to make health chiefs pay for Nexavar, commonly known as sorafenib, would be successful. Mr Ditchfield, of Whalley Road,

Nexavar Shown to Significantly Extend Survival for Patients with ...  -  Feb 11, 2007
PR Newswire (press release),About the SHARP Trial This analysis was conducted using data from the Sorafenib HCC Assessment Randomized Protocol (SHARP) Trial, an international Phase 3

Nexavar® Improves Survival in Liver Cancer  -  Feb 12, 2007
Cancer Consultants (press release),According to a press release from Onyx Pharmaceuticals, Nexavar® (sorafenib) appears to improve overall survival among patients with hepatocellular

Onyx Pharmaceuticals Announces a Teleconference and Webcast to ...  -  Feb 12, 2007
PharmaLive.com (press release),Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation. CONTACT: Julie Wood, +1-510-597-6505, or Alexandra Santos

Onyx Pharmaceuticals Announces a Teleconference and Webcast to ...  -  Feb 11, 2007
PR Newswire (press release),...a conference call on Monday, February 12, 2007, at 10:00 am Eastern Time (7:00 am Pacific Time) to provide an update on Nexavar(R) (sorafenib) tablets.

New drugs in the battle against cancer  -  Feb 4, 2007
ic Wales,Why is it better: Trials have shown that sorafenib can make the cancer stop growing for longer than people taking a placebo. It has also been found to slow

Onyx Pharmaceuticals, Inc. Is Indicating To Open Higher  -  Feb 13, 2007
Trading Markets,...resulting in superior overall survival, or OS, in those patients receiving Nexavar/ sorafenib tablets, compared to those patients receiving placebo.

Bayer, Onyx to Stop Liver Cancer Trial  -  Feb 12, 2007
Houston Chronicle,...showed Nexavar, or sorafenib, significantly increased the survival rate in patients with advanced liver cancer compared with patients taking a placebo.

A Good Day's Work  -  Feb 12, 2007
Corante,They're partners with Bayer on the kinase inhibitor Nexavar (sorafenib), and the companies today reported positive data in treating hepatic cancer.

Onyx Pharmaceuticals Announces Fourth Quarter and Year-End 2006 ...  -  Feb 8, 2007
Earthtimes.orgThe replay will be available through March 15, 2007. NOTE: Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.

Onyx Pharmaceuticals to Present at Merrill Lynch Conference  -  Feb 2, 2007
PharmaLive.com (press release),...visit the company's web site at: www.onyx-pharm.com. NOTE: Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.

Nexavar Shown to Significantly Extend Survival for Patients with ...  -  Feb 13, 2007
PipelineReview.com (press release),This analysis was conducted using data from the Sorafenib HCC Assessment Randomized Protocol (SHARP) Trial, an international Phase 3 double-blind,

Onyx Pharmaceuticals Reports Fourth Quarter and Year-End 2006 ...  -  Feb 15, 2007
Earthtimes.orgOnyx, with its collaborator, Bayer Pharmaceuticals Corporation, or Bayer, is marketing and developing Nexavar(R) (sorafenib) tablets, an anticancer drug

Onyx Pharmaceuticals Shares Flare Up On Positive Nexavar News  -  Feb 12, 2007
Trading Markets,The companies further said the DMC's analysis was conducted using data from the Sorafenib HCC Assessment Randomized Protocol, or SHARP, Trial.

Genta Incorporated Announces Fourth Quarter and Year End 2006 ...  -  Feb 15, 2007
Drug Newswire (press release),...of multiple tyrosine kinase inhibitors, including erlotinib, imatinib, sunitinib and sorafenib, used either alone or in combination with a taxane.

Onyx Pharmaceuticals Reports Fourth Quarter and Year-End 2006 ...  -  Feb 15, 2007
Yahoo! News (press release)Onyx, with its collaborator, Bayer Pharmaceuticals Corporation, or Bayer, is marketing and developing Nexavar® (sorafenib) tablets, an anticancer drug

Immatics Biotech Raises $52M For Cancer Vaccines  -  Feb 13, 2007
BioWorld Online,Although patients with renal cell carcinoma recently have gained new chemotherapy options, namely Sutent (sutinib) and Nexavar (sorafenib),

Biotech Day In Review: Merger Monday  -  Feb 13, 2007
Seeking Alpha,Onyx (ONXX) gained 97% after the company, together with partner Bayer (BAY), reported positive results for cancer drug Nexavar (sorafenib) in patients with

Onyx Doubles on Positive Cancer Drug News  -  Feb 13, 2007
Seeking Alpha,Centient Biotech Investor submits: Onyx (ONXX) and Bayer (BAY) announced positive results for cancer drug Nexavar (sorafenib) in patients with liver cancer.

Onyx/Bayer: Nexavar targets liver cancer  -  Feb 12, 2007
Pharmaceutical Business Review...'Content The pivotal phase III clinical trial comparing first-line Nexavar (sorafenib) with placebo in 602 advanced hepatocellular carcinoma (HCC) patients

Onyx Skyrockets On Phase III Nexavar Data In Liver Cancer  -  Feb 12, 2007
BioWorld Online,...met its primary endpoint earlier than expected, demonstrating superior overall survival in patients receiving Nexavar (sorafenib) tablets over placebo.

Nexavar to extend survival for patients with advanced liver cancer  -  Feb 12, 2007
HULIQ,...endpoint resulting in superior overall survival (OS) in those patients receiving Nexavar® (sorafenib) tablets versus those patients receiving placebo.

Bayer (BAY) and Onyx Phama (ONXX) Said Nexavar Shown to ...  -  Feb 12, 2007
StreetInsider.com (subscription),...endpoint resulting in superior overall survival (OS) in those patients receiving Nexavar® (sorafenib) tablets versus those patients receiving placebo.

Bayer gets boost from success of Nexavar liver study  -  Feb 12, 2007
Pharma Times (subscription),...concluded that the study met its primary endpoint resulting in superior overall survival in those patients receiving Nexavar (sorafenib) versus placebo.

Onyx Pharmaceuticals Announces a Teleconference and Webcast to ...  -  Feb 12, 2007
American Digital Networks (press release),...conference call on Monday, February 12, 2007 , at 10:00 am Eastern Time ( 7:00 am Pacific Time ) to provide an update on Nexavar(R) (sorafenib) tablets.

Onyx Pharmaceuticals Announces a Teleconference and Webcast to ...  -  Feb 11, 2007
Yahoo! News (press release)...a conference call on Monday, February 12, 2007, at 10:00 am Eastern Time (7:00 am Pacific Time) to provide an update on Nexavar® (sorafenib) tablets.

Onyx Pharmaceuticals to Present at BIO CEO and Investor Conference  -  Feb 9, 2007
PR Newswire (press release),...the company's web site at: http://www.onyx-pharm.com. NOTE: Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.

Pfizer sees first-line Sutent OK in the USA  -  Feb 9, 2007
Pharma Times (subscription),And this label expansion also ensures it steals a march on Bayer's new kidney cancer drug Nexavar (sorafenib), which is cleared for second-line use only.

The Future Of Allogeneic Hematopoietic Stem Cell Transplantation ...  -  Feb 5, 2007
Medical News Today (press release),In contrast, targeted therapies (sunitinib, sorafenib, bevacizumab, etc.) have demonstrated significant delays in time to progression, improved survival,

Understand Current Epidemiological Trends in Melanoma and Ongoing ...  -  Jan 30, 2007
Business Wire (press release),As Bayer/Onyxs Nexavar (sorafenib) failed to meet its Phase III primary endpoint of improving progression-free survival in relapsed advanced melanoma

Octreotide of No Benefit in Advanced Liver Cancer  -  Jan 26, 2007
Cancerpage.com,...erlotinib, sorafenib and others) or monoclonal antibodies against vascular endothelial growth factor or epidermal growth factor receptor (bevacizumab,

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional